REPRIEVE Trial Results Have Been Incorporated Into Clinical Guidelines!

The primary results of the REPRIEVE Trial are now available online and show that pitavastatin calcium lowers the incidence rate of heart disease events by 36% in people with HIV. In February 2024, the Department of Health and Human Services Guidelines Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV released recommendations for the use of statin therapy in people with HIV. Click here to learn more about REPRIEVE, read the updated guidelines, and help us spread the word about these exciting results!

REPRIEVE Facts

Bottle-Icon
REPRIEVE evaluated if a statin medication (pitavastatin calcium) is effective to prevent heart disease among people with HIV.
Heart-Pulse-Icon
REPRIEVE is the largest randomized trial to date in HIV and results from REPRIEVE are helping clinical researchers and clinical care providers to develop heart disease prevention and treatment guidelines, specifically for people with HIV.
Number of Participants
7769

Percentage of Women
32%

Mean Age
50

Mean Years Living with HIV
13

Manuscripts Published
45

Retention-Graphic-HOME

Read more about what we’re learning in REPRIEVE

REPRIEVE Publications
REPRIEVE-Promo-Logo-768px

Click here to read about REPRIEVE in the news!

REPRIEVE News

Over 7500 Participants Have Joined REPRIEVE!

Here are two of their stories.

REPRIEVE is a global study

There are over 100 clinical sites in 12 countries around the world

Supporting Organizations